Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.13|
|52 Week High||US$8.88|
|52 Week Low||US$34.79|
|1 Month Change||5.74%|
|3 Month Change||-9.15%|
|1 Year Change||-40.79%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-40.79%|
Recent News & Updates
Athira Pharma: What, Exactly, Did The CEO Do?
CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.
|ATHA||US Pharmaceuticals||US Market|
Return vs Industry: ATHA underperformed the US Pharmaceuticals industry which returned 12.1% over the past year.
Return vs Market: ATHA underperformed the US Market which returned 33.6% over the past year.
Stable Share Price: ATHA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ATHA's weekly volatility (7%) has been stable over the past year.
About the Company
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer’s disease, as well as in clinical development for Parkinson’s disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy.
Is Athira Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ATHA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ATHA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ATHA is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ATHA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATHA is good value based on its PB Ratio (1.1x) compared to the US Pharmaceuticals industry average (3.3x).
How is Athira Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATHA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATHA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATHA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATHA is forecast to have no revenue next year.
High Growth Revenue: ATHA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATHA's Return on Equity is forecast to be high in 3 years time
How has Athira Pharma performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ATHA is currently unprofitable.
Growing Profit Margin: ATHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ATHA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ATHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: ATHA has a negative Return on Equity (-11.12%), as it is currently unprofitable.
How is Athira Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ATHA's short term assets ($290.5M) exceed its short term liabilities ($7.6M).
Long Term Liabilities: ATHA's short term assets ($290.5M) exceed its long term liabilities ($1.8M).
Debt to Equity History and Analysis
Debt Level: ATHA is debt free.
Reducing Debt: ATHA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATHA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ATHA has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 91.2% each year.
What is Athira Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATHA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATHA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Leen Kawas (35 yo)
Dr. Leen Kawas, Ph D., serves as Chief Executive Officer and Director at Athira Pharma, Inc. (former name, M3 Biotechnology, Inc.) since January 2014 and serves as its President. Dr. Kawas served as Vice P...
CEO Compensation Analysis
Compensation vs Market: Leen's total compensation ($USD1.35M) is about average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Leen's compensation has increased whilst the company is unprofitable.
Experienced Management: ATHA's management team is considered experienced (2.2 years average tenure).
Experienced Board: ATHA's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Athira Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Athira Pharma, Inc.
- Ticker: ATHA
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$377.808m
- Shares outstanding: 37.30m
- Website: https://www.athira.com
Number of Employees
- Athira Pharma, Inc.
- 18706 North Creek Parkway
- Suite 104
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 00:54|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.